Skip to main content

BIOPHARMACEUTICS & PHARAMCOKINETIC complete syllabus

  

PHARMACEUTICS-V (BIOPHARMACEUTICS & PHARAMCOKINETICS) (Theory)

Paper 4                                                                                                                                                                                                                                                                                                                          Marks 100

 

1.     DEFINITIONS AND TERMINOLOGY: Biopharmaceutics, Generic Equivalence, Therapeutic Equivalents, Bioavailability, Bioequivalence, Drug Disposition, Pharmacokinetics (LADMER: Libration, absorption, distribution, metabolism, elimination and response).

 

2.     GASTRO-INTESTINAL ABSORPTION: Forces which help in transmembrane movements, Anatomical and physiological factors influencing absorption of drugs. Physicochemical properties of drugs affecting absorption. Absorption of different oral dosage forms.

 

3.     BIOLOGICAL HALF LIFE AND VOLUME OF DISTRIBUTION: Introduction, types, methods of determination and application.

 

4.     DRUG CLEARANCE: Introduction, Mechanism, Models, determination and relationship of clearance with half-life.

 

5.     PHARMACOKINETICS: Introduction, Linear and Non-linear Pharmacokinetics. Application of pharmacokinetics in clinical situations.

 

6.     BIOAVAILABILITY AND BIOEQUIVALENCE:

a.  Introduction.

b.  Bioavailability types, parameters, significance and study protocol.

c.  Methods of Assessment of Bioavailability

d.  Bioequivalence study designs, components and application, report format

 

7.     CONCEPT OF COMPARTMENT(S) MODELS:

I.      One compartment open model

a.     Intravenous Injection (Bolus)

b.     Intravenous infusion

II.    Multicompartment models

a.     Two compartment open model      

b.     IV bolus, IV infusion and oral administration

III.  Non-compartmental Model

a.     Statistical Moment Theory

b.     MRT for various compartment models

c.     Physiological Pharmacokinetic model

 

8.     MULTIPLE DOSAGE REGIMENS:

a.  Introduction: principles of superposition

b.  Factors: persistent, accumulation and loss factors

c.  Repetitive Intravenous injections-One Compartment Open Model

d.  Repetitive Extravascular dosing-One Compartment Open model

e.  Multiple Dose Regimen-Two Compartment Open Model

9.     ELIMINATION OF DRUGS:

d)    Hepatic Elimination: Percent of Drug Metabolized, Drug Biotransformation reactions, (Phase-I reactions and phase-II reactions), First pass effect, Hepatic clearance of protein bound drugs and Biliary excretion of drugs.

e)     Renal Excretion of Drugs: Renal clearance, Tubular Secretion and Tubular Reabsorption.

f)     Elimination of Drugs through other organs: Pulmonary excretion, salivary excretion, Mammilary excretion, Skin excretion and Genital excretion.

10.  PROTEIN BINDING: Introduction, types, kinetics, determination and clinical significance of drug-protein binding.

11.  PHARMACOKINETICS     VARIATIONS           IN DISEASE       STATES:       Determination             of pharmacokinetics variations in renal and hepatic diseases, general approaches for dose adjustment in renal disease and hepatic diseases. 

12.  PHARMACOKINETICS OF INTRAVENOUS INFUSIONS:

13.  BIOPHARMACEUTICAL ASPECTS IN DEVELOPING A DOSAGE FORM: Drug considerations, drug product considerations, patient considerations, manufacturing considerations, pharmacodynamic considerations pharmacokinetic considerations.

IN-VITRO-IN-VIVO CORRELATION (IVIVC): Introduction, levels and determination of invitro/in-vivo correlation.

Comments

Popular posts from this blog

MEDICINAL CHEMISTRY Complete syllabus

    PHARMACEUTICAL CHEMISTRY-IV (MEDICINAL CHEMISTRY) (Theory) Paper 1                                                                                                                                                         ...

Melanocyte Stimulating Hormone (MSH)

    Melanocyte Stimulating Hormone (MSH) •     Secreted by Pars inermedia (intermediate lobe) of pituitary •     Occurs in three different forms (α, β, and γ MSH) •     Biosynthesis: – MSH is the cleavage product of a large precursor peptide called pro-opiomelano cortin (POMC) •     Protease enzyme cleave POMC into ACTH and βlipotropin •     ACTH is further cleaved to form MSH   •     Mechanism: •     Act by binding the G-protein coupled melanocortin 1 receptor (MC1R) on melanocytes – Increases cAMP levels through adenylyl cyclase •     Functions of MSH: •     Stimulate the production and release of melanin from melanocytes in skin & hair (melanogenesis) –   Darkens the skin •     α-MSH acts on hypothalamus –   Suppresses appetite –   Arouse sexually     ...

Adrenocorticotropin

   Adrenocorticotropin •     Also called Adrenocorticotropic Hormone (ACTH) , corticotropin •     Concerned with the growth and functioning of adrenal cortex •     Chemistry: – Single polypeptide with 39 aminoacids •     First 23 amino acids from N-terminal contains biological activity –   Molecular weight 4500 –   Occurs in two forms •      α-corticotropin •      β-corticotropin •      ACTH is synthesized from a glycoprotein called Proopiomelano cortin (POMC) peptide •      POMC is hydrolyzed by different enzymes to form: –   ACTH –   β-Lipotropin –   β-Endorphins  –   Melanocyte Stimulating Hormone (MSH) etc. •     Mechanism of Action •     Ca 2+ ion dependant activation of cAMP – Increased transcription and translation •  ...